Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Toshiyuki Shimakawa"'
Autor:
Koichiro Kinugawa, Moriyoshi Yasuda, Naoki Sato, Takayuki Inomata, Toshiyuki Shimakawa, Yasuhiko Fukuta
Publikováno v:
International heart journal. 60(5)
Tolvaptan, a vasopressin V2 receptor antagonist, is approved in Japan for the treatment of fluid retention in patients with heart failure (HF), and in the United States for hyponatremia. The efficacy and safety of tolvaptan in patients with HF with r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17442c405766e73955fb25298473efcb
https://pubmed.ncbi.nlm.nih.gov/31484861
https://pubmed.ncbi.nlm.nih.gov/31484861
Autor:
Yasuhiko Fukuta, Naoki Sato, Takayuki Inomata, Moriyoshi Yasuda, Koichiro Kinugawa, Toshiyuki Shimakawa
Publikováno v:
Circulation journal : official journal of the Japanese Circulation Society. 83(7)
Background In Japan, tolvaptan is indicated for patients with heart failure and volume overload who have inadequate response to other diuretics. In contrast to the USA and Europe, tolvaptan can be used in Japan in patients with normal sodium levels.M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d8ec34a4402f3b133416dea37293281
https://pubmed.ncbi.nlm.nih.gov/31118355
https://pubmed.ncbi.nlm.nih.gov/31118355
Autor:
Koichiro Kinugawa, Kosuke Bando, Yasuhiko Fukuta, Takayuki Inomata, Toshiyuki Shimakawa, Naoki Sato, Moriyoshi Yasuda
Publikováno v:
International Heart Journal. 58:30-35
The vasopressin receptor 2 (V2) receptor antagonist tolvaptan is an aquaretic agent that has been approved for heart failure patients with volume overload in Japan. In this study (SMILE study), we investigated patient characteristics and effectivenes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::979c12843d5cb1a2a5ec55961d6531e8
https://doi.org/10.1536/ihj.16-249
https://doi.org/10.1536/ihj.16-249
Autor:
Takayuki Inomata, Toshiyuki Shimakawa, Yoshiyuki Shibasaki, Naoki Sato, Koichiro Kinugawa, Moriyoshi Yasuda
Publikováno v:
Circulation journal : official journal of the Japanese Circulation Society. 82(5)
Background It has been 7 years since tolvaptan was approved in Japan for the indication of heart failure in patients with volume overload; the drug can be used in patients with normonatremia. Hypernatremia was identified as a significant adverse even
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c63559cb1114f8a9795e9375845a609
https://pubmed.ncbi.nlm.nih.gov/29607892
https://pubmed.ncbi.nlm.nih.gov/29607892
Autor:
Takayuki Inomata, Naoki Sato, Koichiro Kinugawa, Kazuki Mizuguchi, Toshiyuki Shimakawa, Noriaki Iwatake
Publikováno v:
Circulation Journal. 78:844-852
Background: Loop diuretics are commonly used in heart failure (HF) patients, but they are sometimes associated with insufficient response as well as adverse events. In such diuretics-resistant cases, tolvaptan, a vasopressin type 2 receptor antagonis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f1f878e04622912233f71eed1e1b043
https://doi.org/10.1253/circj.cj-14-0126
https://doi.org/10.1253/circj.cj-14-0126
Autor:
Koichiro, Kinugawa, Takayuki, Inomata, Naoki, Sato, Moriyoshi, Yasuda, Toshiyuki, Shimakawa, Kosuke, Bando, Yasuhiko, Fukuta
Publikováno v:
International heart journal. 58(1)
The vasopressin receptor 2 (V2) receptor antagonist tolvaptan is an aquaretic agent that has been approved for heart failure patients with volume overload in Japan. In this study (SMILE study), we investigated patient characteristics and effectivenes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3f51a9fe6227eb6f7daf34a571fdf274
https://pubmed.ncbi.nlm.nih.gov/28111410
https://pubmed.ncbi.nlm.nih.gov/28111410
Autor:
Koichiro Kinugawa, Kosuke Bando, Moriyoshi Yasuda, Takayuki Inomata, Kazuki Mizuguchi, Naoki Sato, Toshiyuki Shimakawa
Publikováno v:
International heart journal. 56(2)
The vasopressin receptor 2 (V2) receptor antagonist tolvaptan is an aquaretic agent that has been found to improve symptoms in patients with congestive heart failure. In this study (SMILE study), we administered tolvaptan to patients aged ≥ 80 year
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5036a1d6057a473a444fe0f31278ca3e
https://pubmed.ncbi.nlm.nih.gov/26346521
https://pubmed.ncbi.nlm.nih.gov/26346521
Autor:
Koichiro, Kinugawa, Naoki, Sato, Takayuki, Inomata, Toshiyuki, Shimakawa, Noriaki, Iwatake, Kazuki, Mizuguchi
Publikováno v:
Circulation journal : official journal of the Japanese Circulation Society. 78(4)
Loop diuretics are commonly used in heart failure (HF) patients, but they are sometimes associated with insufficient response as well as adverse events. In such diuretics-resistant cases, tolvaptan, a vasopressin type 2 receptor antagonist, shows the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bb586fc4066813ecba16e044cd7c0d02
https://pubmed.ncbi.nlm.nih.gov/24670835
https://pubmed.ncbi.nlm.nih.gov/24670835
Autor:
Kosuke Bando, Takayuki Inomata, Naoki Sato, Kazuki Mizuguchi, Moriyoshi Yasuda, Toshiyuki Shimakawa, Koichiro Kinugawa
Publikováno v:
International Heart Journal. 56:581-581
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9f02245451e99b3ce965d5585f7e1597
https://doi.org/10.1536/ihj.56-5_errata1
https://doi.org/10.1536/ihj.56-5_errata1